Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
Clin Cancer Res. 2022 Sep 15;28(18):3929-3939. doi: 10.1158/1078-0432.CCR-21-3304.
Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.
近年来，在制造、修饰、纯化和细胞递送上的进展，使得 RNA 为基础的治疗方法在广泛的应用领域得以发展。两种针对 SARS-CoV-2 的靶向 mRNA 疫苗的批准凸显了这一技术的进步。该技术具有快速、直接的制造、临床安全性和多功能性，为 RNA 治疗方法扩展到癌症免疫治疗铺平了道路。随着 RNA 癌症疫苗接种和细胞治疗的持续试验，RNA 治疗方法可能会被引入临床实践，为未来的个性化方法提供可能。在本综述中，我们讨论了 RNA 免疫肿瘤学的最新进展，并更新了正在进行的临床应用及其当前的挑战。
